1988
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Cedarbaum J, Kutt H, McDowell F. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988, 38: 533-6. PMID: 3352906, DOI: 10.1212/wnl.38.4.533.Peer-Reviewed Original ResearchConceptsDaily intakeRecent clinical trialsMean daily intakeTotal daily intakeLevodopa intakeStandard SinemetClinical responseLevodopa preparationsBrain uptakeClinical trialsPlasma concentrationsClinical significanceBlood samplingLevodopaTherapeutic efficacyMethyldopa levelsControlled-release formulationPatientsIntakeTime curveAUCSinemetLevelsTrials
1987
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Cedarbaum J, Breck L, Kutt H, McDowell F. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 1987, 37: 1607-12. PMID: 3658164, DOI: 10.1212/wnl.37.10.1607-a.Peer-Reviewed Original ResearchConceptsSinemet CR4Interdose intervalParkinson's diseaseResponse fluctuationsTherapeutic response fluctuationsOpen-label trialPlasma levodopa levelsSlow-release preparationAntiparkinsonian effectsStandard levodopaLevodopa dosesLevodopa preparationsLevodopa levelsDaily dosesRelease preparationDiseaseLevodopaDosesProlongationTreatmentOverall benefitSinemetPatientsSlight reductionControlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum J, Breck L, Kutt H, McDowell F. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease. Neurology 1987, 37: 233-41. PMID: 3808304, DOI: 10.1212/wnl.37.2.233.Peer-Reviewed Original ResearchConceptsPlasma levodopa levelsLevodopa levelsResponse fluctuationsParkinson's diseaseControlled-release carbidopa/levodopaCarbidopa/levodopaOpen-label trialBioavailability of levodopaStandard SinemetDisability scoresLevodopa preparationsInterdose intervalDaily dosesParkinson's patientsControlled-release formulationClinical performanceDiseaseLevodopaDay consistencyOverall benefitSinemetPatientsDosesTrialsWeeks